Price Alert

Novo Nordisk A/S (NONOF)

OTC: NONOF · Real-Time Price · USD

52.37

2.11 (4.20%)

At close: Aug 15, 2025, 3:44 PM

51.00

-2.61%

Pre-market: Aug 15, 2025, 11:51 AM EDT

Novo Nordisk A/S Income Statement

Financials in DKK. Fiscal year is undefined.

Fiscal Year	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Revenue	78.09B	85.68B	71.31B	68.06B	65.35B	65.86B	58.73B	54.3B	53.37B	48.09B	45.57B	41.27B	42.03B	38.33B	35.62B	33.04B	33.8B
Cost of Revenue	12.89B	13.02B	11.31B	10.27B	9.92B	10.01B	9.71B	7.86B	8.18B	8.26B	7.2B	6.07B	6.92B	6.24B	6.06B	5.55B	5.81B
Gross Profit	65.2B	72.66B	60B	57.79B	55.43B	55.85B	49.02B	46.44B	45.19B	39.83B	38.37B	35.2B	35.11B	32.09B	29.56B	27.49B	27.99B
Operating Income	38.79B	36.74B	33.82B	25.53B	31.85B	26.77B	26.91B	23.89B	25.01B	8.28B	20.18B	18.39B	19.15B	13.63B	15.25B	14.78B	14.98B
Interest Income	3.42B	n/a	1.38B	960M	2.15B	n/a	3.32B	647M	852M	n/a	1.57B	1.66B	210M	n/a	790M	138M	1.75B
Pretax Income	37.03B	35.56B	34.38B	25.33B	31.92B	27.62B	28.06B	24.25B	24.74B	16.32B	18.03B	16.8B	17.92B	13.11B	15.11B	14.92B	15.94B
Net Income	29.03B	28.23B	27.3B	20.05B	25.41B	21.96B	22.48B	19.43B	19.81B	13.59B	14.4B	13.32B	14.21B	10.89B	12.12B	12.12B	12.62B
Selling & General & Admin	16.11B	20.28B	16.59B	16.09B	14.41B	18.63B	14.07B	15.41B	13.48B	15.09B	12.61B	11.83B	11.15B	12.82B	10.14B	8.9B	9.19B
Research & Development	10.31B	13.8B	9.49B	16.17B	8.61B	10.46B	8.13B	7.13B	6.73B	8.09B	5.63B	5.12B	5.21B	5.63B	4.25B	3.94B	3.94B
Other Expenses	-14M	1.84B	101M	n/a	568M	-3M	-98M	15M	-33M	-433M	-60M	-149M	-392M	4M	-81M	-134M	-121M
Operating Expenses	26.41B	35.92B	26.18B	32.26B	23.59B	29.08B	22.11B	22.56B	20.18B	22.74B	18.18B	16.8B	15.97B	18.46B	14.31B	12.71B	13.01B
Interest Expense	5.18B	n/a	821M	1.56B	2.07B	n/a	2.17B	281M	1.12B	n/a	3.73B	3.25B	1.44B	n/a	927M	n/a	797M
Selling & Marketing Expenses	14.89B	18.7B	15.21B	14.93B	13.26B	17.17B	12.82B	14.34B	12.41B	13.74B	11.45B	10.84B	10.18B	11.63B	9.12B	8B	8.26B
Cost & Expenses	39.3B	48.95B	37.39B	42.53B	32.94B	39.1B	31.82B	30.41B	28.36B	31B	25.38B	22.87B	22.88B	24.7B	20.37B	18.26B	18.82B
Income Tax Expense	8B	7.33B	7.08B	5.28B	6.51B	5.66B	5.58B	4.83B	4.92B	2.72B	3.63B	3.48B	3.71B	2.22B	2.99B	2.79B	3.31B
Shares Outstanding (Basic)	4.44B	4.45B	4.45B	4.46B	4.46B	4.46B	4.5B	4.49B	4.5B	4.51B	4.52B	4.54B	4.55B	4.58B	4.59B	4.61B	4.63B
Shares Outstanding (Diluted)	4.45B	4.46B	4.46B	4.47B	4.47B	4.48B	4.49B	4.5B	4.51B	4.52B	4.54B	4.55B	4.57B	4.58B	4.6B	4.61B	4.63B
EPS (Basic)	6.54	6.34	6.13	4.50	5.70	4.92	5.02	4.33	8.81	6.01	3.17	2.93	3.11	4.75	5.29	5.26	5.47
EPS (Diluted)	6.53	6.33	6.12	4.49	5.68	4.91	5.00	4.32	8.78	5.99	3.18	2.93	3.11	4.75	5.27	5.26	5.45
EBITDA	46.05B	40.14B	37.35B	35.74B	35.33B	30.61B	29.44B	26.71B	27.58B	19.12B	23.8B	21.68B	21.01B	15.97B	17.39B	16B	18.11B
EBIT	42.22B	34.94B	35.2B	26.89B	31.85B	25.52B	26.91B	24.54B	25.01B	17.09B	20.18B	18.39B	19.15B	11.73B	15.25B	14.78B	14.98B
Depreciation & Amortization	3.83B	5.2B	2.15B	8.85B	2.91B	2.99B	2.52B	2.18B	1.72B	2.04B	2.04B	1.64B	1.65B	2.08B	1.35B	1.22B	1.38B